The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Nanatinostat plus valganciclovir granted Fast Track designation by the FDA for the treatment of patients with EBV-associated lymphomas
On the 12th November 2019, the combination of nanatinostat with valganciclovir was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory (R/R) Epstein-Barr virus (EBV)-positive lymphoma.1
The Fast Track status was granted based on the positive interim data from the ongoing phase Ib/IIa clinical trial [NCT03397706], investigating the combination in patients with R/R EBV-positive lymphomas.2 The combination was well tolerated and showed responses in B- and T-cell malignancies, with the overall response rate of 58%, complete response rate of 33%, and disease stabilization rate of 75%. The updated clinical data are expected to be presented at the annual meeting of American Society of Hematology (ASH) in December 2019.
Nanatinostat (VRx-3996) is an orally available inhibitor of Class 1 histone deacetylase (HDAC), an enzyme important for epigenetic control of gene expression, including induction of genes responsible for EBV latency. The inhibition of HDAC reactivates the EBV lytic cycle in EBV-positive cells, sensitizing EBV-infected cells to antiviral therapy with valganciclovir and therefore enhancing the anti-tumour activity.
References